Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.02Last Year’s EPS
-0.14Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 5.90%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment driven by strong growth in LUMRYZ adoption and favorable legal outcomes, alongside raised financial guidance. However, some caution remains due to typical Q1 seasonality effects and potential impacts from ongoing legal and tariff challenges.Company Guidance
During Avadel Pharmaceuticals' First Quarter 2025 earnings call, the company provided several important metrics and updates, highlighting their confidence in continued growth. LUMRYZ, their key product, experienced significant progress with accelerated patient adoption, leading to 100% growth in patient numbers compared to the same period last year, ending the quarter with 2,800 patients. Additionally, the net new patient count increased by 50% from the previous quarter, with 300 new patients starting therapy. Despite typical Q1 seasonality, Avadel reported $52.5 million in net revenue, marking over 90% growth versus Q1 2024. The company raised its full-year revenue guidance to a range of $255 million to $265 million, up from the previous guidance of $240 million to $260 million, and expects to end the year with 3,400 to 3,600 patients on LUMRYZ. Their strategic investments, including a 15% increase in sales force and doubled field reimbursement and nursing support teams, have been instrumental in improving patient enrollments, new patient starts, and persistency rates, driving continued momentum and growth throughout 2025.Strong Growth in LUMRYZ Adoption
LUMRYZ saw accelerated patient adoption with 2,800 patients by the end of Q1 2025, reflecting 100% growth over the same period last year.
Favorable Court Decision
Avadel received a favorable decision from the Federal Circuit Court of Appeals, allowing them to pursue additional indications for LUMRYZ beyond narcolepsy.
Increased Financial Guidance
Avadel raised its full year 2025 revenue guidance to $255 million to $265 million, up from $240 million to $260 million.
Expansion of Commercial Teams
Avadel expanded its sales force by 15% and doubled the size of both its field reimbursement and nursing support teams, contributing to increased patient starts and improved persistency.
Substantial Revenue Growth
Reported net revenue of $52.5 million in Q1 2025, representing greater than 90% growth versus Q1 2024.
AVDL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AVDL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $8.64 | $9.47 | +9.61% |
Mar 03, 2025 | $7.91 | $7.55 | -4.55% |
Nov 12, 2024 | $16.30 | $13.15 | -19.33% |
Aug 08, 2024 | $16.10 | $15.74 | -2.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Avadel Pharmaceuticals (AVDL) report earnings?
Avadel Pharmaceuticals (AVDL) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Avadel Pharmaceuticals (AVDL) earnings time?
Avadel Pharmaceuticals (AVDL) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVDL EPS forecast?
AVDL EPS forecast for the fiscal quarter 2025 (Q2) is 0.02.